MAP Pharmaceuticals, Inc. (MAPP) Reports Q1 EPS Loss of $0.58

MAP Pharmaceuticals, Inc. (NASDAQ: MAPP) reported Q1 EPS of ($0.58), $0.19 worse than the analyst estimate of ($0.39). Revenue for the quarter came in at $34.2 million, which may not compare to the consensus estimate of $820 thousand.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Micron Technology (MU) Tops Q4 EPS by $2.26, Offers Guidance
• IDT Corp. (IDT) Misses Q4 EPS by 3c
• FactSet (FDS) Tops Q4 EPS by 17c, Beats on Revenue; Offers FY Guidance